We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$916M
AUM Growth
+$22.5M
Cap. Flow
+$9.33M
Cap. Flow %
1.02%
Top 10 Hldgs %
50.42%
Holding
61
New
8
Increased
22
Reduced
19
Closed
5

Top Buys

Rank Stock Value
1
CALA
Calithera Biosciences, Inc
CALA
+$21.2M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$16.4M
3
CYTK icon
Cytokinetics
CYTK
+$13.3M
4
AKRO
Akero Therapeutics
AKRO
+$12.3M
5
ACIU icon
AC Immune
ACIU
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$62.5M
2
ARQL
Arqule Inc
ARQL
+$38.5M
3
BPMC
Blueprint Medicines
BPMC
+$10.5M
4
ARGX icon
argenx
ARGX
+$10.1M
5
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$8.83M

Sector Composition

Rank Sector Weight
1 Healthcare 90.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$68M 7.42%
4,639,413
+99,500
+2% +$1.41M
CYTK icon
2
Cytokinetics
CYTK
$10.9B
$58.2M 6.36%
5,176,878
+1,375,061
+36% +$13.3M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$55.3M 6.04%
1,193,224
-2,227,338
-65% -$62.5M
ACIU icon
4
AC Immune
ACIU
$241M
$54.5M 5.95%
9,819,434
+2,363,900
+32% +$12M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$54.3M 5.93%
527,253
+95,553
+22% +$7.44M
KURA icon
6
Kura Oncology
KURA
$826M
$43.4M 4.74%
2,204,119
-291,037
-12% -$4.83M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$41.3M 4.51%
437,565
-127,400
-23% -$10.5M
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$31.4M 3.43%
17,426,968
– –
RCUS icon
9
Arcus Biosciences
RCUS
$3.55B
$28.1M 3.07%
3,535,223
+725,000
+26% +$7.26M
MTEM
10
DELISTED
Molecular Templates, Inc.
MTEM
$27.2M 2.97%
217,101
-21,508
-9% -$2.34M
XOMA
11
DELISTED
Xoma
XOMA
$26.7M 2.92%
1,796,942
+27,913
+2% +$419K
CALA
12
DELISTED
Calithera Biosciences, Inc
CALA
$26.3M 2.88%
337,524
+186,350
+123% +$21.2M
REPL icon
13
Replimune Group
REPL
$25.3M 2.76%
1,724,609
+117,792
+7% +$1.7M
CTMX icon
14
CytomX Therapeutics
CTMX
$714M
$21M 2.3%
1,873,617
+675,617
+56% +$7.08M
CNCE
15
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$19.5M 2.13%
1,628,187
+242,700
+18% +$2.61M
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$19.3M 2.11%
1,223,925
-177,031
-13% -$2.41M
PVLA
17
Palvella Therapeutics
PVLA
$2.15B
$18.6M 2.03%
49,428
-1,302
-3% -$388K
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.1M 1.98%
3,003,342
-61,004
-2% -$583K
XENE icon
19
Xenon Pharmaceuticals
XENE
$6.2B
$17.2M 1.88%
1,741,600
-47,174
-3% -$451K
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.73B
$16.4M 1.79%
1,764,784
-222,885
-11% -$1.62M
IDYA icon
21
IDEAYA Biosciences
IDYA
$3.5B
$15M 1.64%
+1,505,429
New +$16.4M
GLMD icon
22
Galmed Pharmaceuticals
GLMD
$4.95M
$13.5M 1.47%
10,180
-256
-2% -$330K
CCXI
23
DELISTED
ChemoCentryx, Inc.
CCXI
$13.2M 1.44%
1,414,515
-50,000
-3% -$579K
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.92B
$12.9M 1.41%
1,063,802
-59,453
-5% -$657K
AKRO
25
DELISTED
Akero Therapeutics
AKRO
$12.4M 1.36%
+648,348
New +$12.3M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2019 Portfolio in Review

As of Q2 2019, BVF Inc held 61 positions worth $916M, up 2.5% from $893M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc's Q2 2019 filing shows 8 new, 22 increased, 19 reduced and 5 closed positions. Its largest new stake was IDEAYA Biosciences: 1,505,429 shares worth $15M. The largest sale was Array Biopharma Inc, an estimated $62.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

  • BVF Inc's largest Q2 2019 buy was IDEAYA Biosciences: 1,505,429 shares worth $15M.
  • BVF Inc added most to Calithera Biosciences, Inc in Q2 2019, an estimated $21.2M increase.
  • BVF Inc's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.5M.
  • BVF Inc fully exited argenx in Q2 2019, selling an estimated $10.1M.
  • BVF Inc's ten largest holdings make up 50% of its $916M portfolio in Q2 2019.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2019.
  • BVF Inc's portfolio value rose 2.5% quarter-over-quarter to $916M.

Based on BVF Inc's 13F filing for Q2 2019, filed 14 Aug 2019.